Bionomics’ (BNOX) Outperform Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Bionomics (NASDAQ:BNOX) in a report published on Friday,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Bionomics in a research report on Thursday, August 1st.

Bionomics Stock Down 8.1 %

Shares of Bionomics stock opened at $0.29 on Friday. The stock’s fifty day moving average is $0.40 and its 200-day moving average is $0.63. Bionomics has a 12-month low of $0.18 and a 12-month high of $2.19.

Institutional Investors Weigh In On Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC purchased a new position in Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics at the end of the most recent reporting period. 15.90% of the stock is owned by hedge funds and other institutional investors.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.